India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus India's obesity-drug market could be entering a new phase as Novo Nordisk ( NYSE:NVO ) approaches the expiration of its key semaglutide patent in the country on March 20. The patent loss may allow several Indian pharmaceutical companies including Mankind Pharma, Ajanta Pharma, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories and Lupin to launch lower-cost versions of the active ingredient used in Ozempic and Wegovy. These generic therapies are expected to be at least 50% cheaper than Novo's treatment, potentially priced around 5,000 rupees per weekly dose, a shift that could broaden access to weight-loss medications across the country. Warning! GuruFocus has detected 2 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Healthcare providers across India are already preparing for a possible surge in demand. Hospital groups such as Apollo Health & Lifestyle and Fortis Healthcare are expandin
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- India's Zydus, Lupin sign deal to co-market Semaglutide injections [Yahoo! Finance]Yahoo! Finance
- Strait of Hormuz standoff puts supply of America's generic drug prescriptions at risk [MSNBC.com]MSNBC.com
- Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Ticagrelor Market Size to Reach USD 3.60 Billion by 2035, Fueled by Rising Cardiovascular Disease Burden and Growing Adoption of Advanced Antiplatelet Therapies – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Prolonged Strait of Hormuz standoff will close in on America's generic drug prescriptions [CNBC]CNBC
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 3/13/26 - Form 6-K
- 3/12/26 - Form 6-K
- 3/12/26 - Form 6-K
- RDY's page on the SEC website